2024

1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

   Future Oncology, Vol. 20, Núm. 13, pp. 799-809

2. An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)

   International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945

3. Antibody-drug conjugate targeting folate receptor α: a new milestone in personalized medicine for high-grade serous ovarian cancer

   International Journal of Gynecological Cancer

4. Assessing minimally invasive simple hysterectomy in low risk cervical cancer: set up for the LASH trial

   International Journal of Gynecological Cancer

5. Best original research presented at the 25th European Congress on Gynaecological Oncology: Best of ESGO 2024

   International Journal of Gynecological Cancer

6. Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer

   Seminars in Oncology Nursing, Vol. 40, Núm. 1

7. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

   Gynecologic Oncology, Vol. 187, pp. 128-138

8. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

   Advances in Therapy

9. HRD testing for all advanced high-grade ovarian carcinoma in first line?

   ESMO Open

10. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study

    Gynecologic Oncology, Vol. 186, pp. 182-190

11. Maternal and Fetal Outcomes after Multiple Cesarean Deliveries

    Journal of Clinical Medicine, Vol. 13, Núm. 15

12. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621

13. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Annals of Oncology

14. Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic

    Archives of Gynecology and Obstetrics, Vol. 310, Núm. 1, pp. 577-586

15. Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012

    Gynecologic Oncology, Vol. 189, pp. 68-74

16. Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe

    International Journal of Gynecological Cancer

17. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 7, pp. 1041-1050

18. Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line

    Clinical and Translational Oncology

19. Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study

    BMC Cancer, Vol. 24, Núm. 1

20. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321